Exploiting viral properties for the rational design of modern vaccines

References

• Plotkin SA. Vaccines: past, present and future. Nat. Med.11(Suppl. 4), S5–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med.11(Suppl. 4), S54–S62 (2005).
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J. Control. Release79(1–3), 29–40 (2002).
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol.173(5), 3148–3154 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell111(7), 927–930 (2002).
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF, Fehr T, Lutz C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science286(5447), 2156–2159 (1999).
   PubMed Web of Science ®Google Scholar
• Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol.16, 545–568 (1998).
   PubMedGoogle Scholar
• Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol.5(7), 678–684 (2004).
   PubMed Web of Science ®Google Scholar
• Elliott T, Neefjes J. The complex route to MHC class I–peptide complexes. Cell127(2), 249–251 (2006).
   Google Scholar
• Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA90(11), 4942–4946 (1993).
   PubMed Web of Science ®Google Scholar
• Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J. Immunol.172(10), 6129–6135 (2004).
   PubMed Web of Science ®Google Scholar
• Ikomi F, Hanna GK, Schmid-Schonbein G. Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology32(3), 90–102 (1999).
   PubMed Web of Science ®Google Scholar
• Kamantigue E, Edwards W 3rd, Chada S et al. Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther.3(2), 128–136 (1996).
   Google Scholar
• West AP, Koblansky AA, Ghosh S. Recognition and signaling by Toll-like receptors. Annu. Rev. Cell Dev. Biol.22, 409–437 (2006).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol.7(3), 179–190 (2007).
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell22(5), 561–569 (2006).
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S et al. 5´-triphosphate RNA is the ligand for RIG-I. Science314(5801), 994–997 (2006).
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5´-phosphates. Science314(5801), 997–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature448(7152), 501–505 (2007).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat. Immunol.7(2), 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Zinkernagel RM. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today17(12), 553–558 (1996).
   PubMedGoogle Scholar
• Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu. Rev. Immunol.15, 235–270 (1997).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol.25(12), 3445–3451 (1995).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol.169(11), 6120–6126 (2002).
   PubMed Web of Science ®Google Scholar
• Dintzis RZ, Vogelstein B, Dintzis HM. Specific cellular stimulation in the primary immune response: experimental test of a quantized model. Proc. Natl Acad. Sci. USA79(3), 884–888 (1982).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Storni T, Lipowsky G et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol.32(11), 3305–3314 (2002).
   PubMed Web of Science ®Google Scholar
• Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol.2(4), 251–262 (2002).
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol.78(11), 5535–5545 (2004).
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol.163(7), 3735–3745 (1999).
   PubMed Web of Science ®Google Scholar
• Kundig TM, Shahinian A, Kawai K et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity5(1), 41–52 (1996).
   PubMed Web of Science ®Google Scholar
• van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol.2(5), 423–429 (2001).
   Google Scholar
• Mercado R, Vijh S, Allen SE et al. Early programming of T cell populations responding to bacterial infection. J. Immunol.165(12), 6833–6839 (2000).
   PubMedGoogle Scholar
• Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity8(1), 89–95 (1998).
   PubMed Web of Science ®Google Scholar
• van Stipdonk MJ, Hardenberg G, Bijker MS et al. Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol.4(4), 361–365 (2003).
   Google Scholar
• Storni T, Ruedl C, Renner WA, Bachmann MF. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J. Immunol.171(2), 795–801 (2003).
   PubMedGoogle Scholar
• Chao CC, Jensen R, Dailey MO. Mechanisms of L-selectin regulation by activated T cells. J. Immunol.159(4), 1686–1694 (1997).
   PubMed Web of Science ®Google Scholar
• Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol.161(10), 5338–5346 (1998).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Beerli RR, Agnellini P et al. Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur. J. Immunol.36(4), 842–854 (2006).
   PubMed Web of Science ®Google Scholar
• Sinha RK, Khuller GK. The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice. Immunol. Cell Biol.75(5), 461–466 (1997).
   Google Scholar
• Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine15(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Pennington R, Boni L et al. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol.160(8), 3637–3641 (1998).
   PubMed Web of Science ®Google Scholar
• Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol.64(6), 713–723 (1998).
   PubMed Web of Science ®Google Scholar
• Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol. Cell Biol.83(2), 119–128 (2005).
   PubMed Web of Science ®Google Scholar
• Smith RE, Donachie AM, Mowat AM. Immune stimulating complexes as mucosal vaccines. Immunol. Cell Biol.76(3), 263–269 (1998).
   PubMed Web of Science ®Google Scholar
• Gamvrellis A, Leong D, Hanley JC et al. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol.82(5), 506–516 (2004).
   PubMed Web of Science ®Google Scholar
• Wang C, Ge Q, Ting D et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater.3(3), 190–196 (2004).
   PubMed Web of Science ®Google Scholar
• Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan – DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med.5(4), 387–391 (1999).
   PubMed Web of Science ®Google Scholar
• Beyer T, Herrmann M, Reiser C, Bertling W, Hess J. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr. Drug Targets Infect. Disord.1(3), 287–302 (2001).
   PubMedGoogle Scholar
• Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8- dendritic cells: a dispensable role for TAP. Eur. J. Immunol.32(3), 818–825 (2002).
   PubMed Web of Science ®Google Scholar
• Barth H, Ulsenheimer A, Pape GR et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood105(9), 3605–3614 (2005).
   PubMed Web of Science ®Google Scholar
• Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl Acad. Sci. USA94(14), 7503–7508 (1997).
   PubMed Web of Science ®Google Scholar
• Moron VG, Rueda P, Sedlik C, Leclerc C. in vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol.171(5), 2242–2250 (2003).
   PubMed Web of Science ®Google Scholar
• Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res63(13), 3478–3482 (2003).
   PubMed Web of Science ®Google Scholar
• Buseyne F, Le Gall S, Boccaccio C et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med.7(3), 344–349 (2001).
   Google Scholar
• Wan Y, Wu Y, Zhou J et al. Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments. Eur. J. Immunol.35(7), 2041–2050 (2005).
   Google Scholar
• Bachmann MF, Schwarz K, Wolint P et al. Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells. J. Immunol.173(4), 2217–2221 (2004).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Maurer P, Bessa J et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol.178(4), 2415–2420 (2007).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Ugozzoli M et al. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv.3(1), 115–120 (2006).
   PubMedGoogle Scholar
• Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.107(1), 18–27 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines6(3), 381–390 (2007).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot A, Lechner F et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine20(25–26), 3104–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest.108(3), 415–423 (2001).
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol.35(7), 2031–2040 (2005).
   PubMed Web of Science ®Google Scholar
• Kundig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol.117(6), 1470–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Spohn G, Schwarz K, Maurer P et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol.175(9), 6211–6218 (2005).
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot AC, Fulurija A et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J. Hypertens.25(1), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Spohn G, Bachmann MF. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin. Biol. Ther.3(3), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Spohn G, Guler R, Johansen P et al. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol.178(11), 7450–7457 (2007).
   PubMed Web of Science ®Google Scholar
• Li Q, Cao C, Chackerian B et al. Overcoming antigen masking of anti-amyloidβ antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci.5, 21–(2004).
   PubMedGoogle Scholar
• Rohn TA, Jennings GT, Hernandez M et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol.36(11), 2857–2867 (2006).
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J et al. Vaccination against angiotensin II reduces day-time and early morning ambulatory blood pressure: results of a randomized placebo-controlled Phase IIa study with CYT006-AngQb. Lancet (2008) (in press).
   Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation.Nat. Rev. Drug Discov.5(6), 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Angel JB et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS19(14), 1473–1479 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine22(23–24), 3136–3143 (2004).
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl J. Med.355(14), 1445–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res.23(6), 1217–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol.79(5), 2910–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother.48(6), 751–755 (2001).
   PubMed Web of Science ®Google Scholar
• Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol.204(1), 64–74 (2000).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med.10(2), 187–192 (2004).
   PubMed Web of Science ®Google Scholar
• Storni T, Ruedl C, Schwarz K et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol.172(3), 1777–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (1997), 27(6), 460–471 (2004).
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol.176(12), 7335–7345 (2006).
   PubMed Web of Science ®Google Scholar
• Westwood A, Elvin SJ, Healey GD, Williamson ED, Eyles JE. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Vaccine24(11), 1736–1743 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshida H, Horie H, Matsuura K, Miyamura T. Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan. Lancet356(9240), 1461–1463 (2000).
   PubMedGoogle Scholar
• Nathanson N, Fine P. Virology. Poliomyelitis eradication – a dangerous endgame. Science296(5566), 269–270 (2002).
   Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl Acad. Sci. USA96(5), 2373–2378 (1999).
   PubMed Web of Science ®Google Scholar
• Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA95(4), 1800–1805 (1998).
   PubMed Web of Science ®Google Scholar
• Tegerstedt K, Lindencrona JA, Curcio C et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res.65(13), 5953–5957 (2005).
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology290(2), 350–360 (2001).
   Google Scholar
• Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials28(35), 5344–5357 (2007).
   PubMed Web of Science ®Google Scholar